Zepbound (tirzepatide) is a dual GLP-1/GIP receptor agonist primarily approved for chronic weight management, and also for type 2 diabetes (as Mounjaro), working by enhancing insulin secretion, slowing gastric emptying, and reducing appetite
There is no official contraindication to using Wegovy in patients who have had their gallbladder removed
Your muscles see most of this action, which, as you might expect, explains why active people usually see better results
We ask you to be understanding of this situation and if you notice a discrepancy - let us know
This can lead to: Weakness Fatigue Slower metabolism Increased risk of weight regain later Protecting muscle is one of the most important parts of healthy medical weight loss
Nausea is the most common side effect of semaglutide, affecting up to 44% of patients taking Wegovy and approximately 15-20% of those on Ozempic